Mannitol inhalation - Pharmaxis

Drug Profile

Mannitol inhalation - Pharmaxis

Alternative Names: Bronchitol; Mannitol dry powder for inhalation - Pharmaxis; Precision spray‐dried mannitol

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Royal Prince Alfred Hospital
  • Developer Pharmaxis
  • Class Small molecules; Sugar alcohols
  • Mechanism of Action Osmotic diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis; Cystic fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes - Bronchiectasis; Cystic fibrosis

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase III Bronchiectasis
  • Discontinued Allergic rhinitis; Sinusitis

Most Recent Events

  • 13 Jun 2017 Pharmaxis announces intention to resubmit NDA to US FDA in 2018
  • 13 Jun 2017 Efficacy and adverse events data from a pivotal phase III trial in Cystic fibrosis released by Pharmaxis
  • 13 Jun 2017 Pharmaxis completes a pivotal phase III trial in Cystic fibrosis (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top